Methods for metabolic evaluation of prostate cancer cells using proton and 13C HR-MAS spectroscopy and [3-13C] pyruvate as a metabolic substrate

Magnetic Resonance in Medicine

Volumn 62, Issue 5, 2009, Pages 1091-1098

  Levin, Yakir S ^a   Albers, Mark J ^b   Butler, Thomas N ^b   Spielman, Daniel ^a   Peehl, Donna M ^c   Kurhanewicz, John ^b  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

13C pyruvate; 1H HR MAS spectroscopy; Bioenergetic theory; Citric acid cycle; HSQC; Prostate cancer primary cell cultures

Indexed keywords

AMINO ACIDS; CELL CULTURE; CELLS; MAGIC ANGLE SPINNING; METABOLISM; METABOLITES; PROBES; SUBSTRATES; TRANSPLANTS; UROLOGY;

BIOENERGETIC THEORY; HIGH RESOLUTION MAGIC ANGLE SPINNING; HSQC; LACTATE CONCENTRATION; NEOPLASTIC TRANSFORMATION; PRIMARY CELL CULTURES; PROSTATE CANCER CELLS; PYRUVATES;

DISEASES;

ALANINE; ASPARTIC ACID; CARBON 13; CITRIC ACID; GLUTAMIC ACID; LACTIC ACID; PYRUVIC ACID;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL METABOLISM; CELL TRANSFER; CITRIC ACID CYCLE; CONTROLLED STUDY; ENERGY TRANSFER; GLEASON SCORE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REPRODUCIBILITY;

EID: 70449411175     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22120     Document Type: Article

References (28)

1. Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, Narayan P. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995;45:459-466.
2. 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 1993;29:149-157.
3. Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, Lutz O. Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn Reson Med 1993;29:38-43. (Pubitemid 23063067)
4. 31P magnetic resonance spectroscopy. J Urol 1993;150:2019-2024.
5. 1H HR-MAS spectroscopy. Magn Reson Med 2006;55:1257-1264.
6. 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med 2008;60:510-516.
7. Costello LC, Franklin RB. Bioenergetic theory of prostate malignancy. Prostate 1994;25:162-166.
8. Costello LC, Franklin RB. Why do tumour cells glycolyse? From glycolysis through citrate to lipogenesis. Mol Cell Biochem 2005;280:1-8.
9. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-899.
10. Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005;12:19-47.
11. Peehl DM. Human prostatic epithelial cells. In: Freshney RI, Freshney MG, editors. Culture of epithelial cells. 2nd ed. New York: Wiley-Liss; 2002. p 171-194.
12. Yacoe ME, Sommer G, Peehl D. In vitro proton spectroscopy of normal and abnormal prostate. Magn Reson Med 1991;19:429-438.
13. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med 2003;50:944-954. (Pubitemid 37356574)
14. 1H NMR spectroscopy at 9.4 T. FEBS Lett 2001;494:112-116.
15. Griffin JL, Blenkiron C, Valonen PK, Caldas C, Kauppinen RA. High-resolution magic angle spinning 1H NMR spectroscopy and reverse transcription-PCR analysis of apoptosis in a rat glioma. Anal Chem 2006;78:1546-1552. (Pubitemid 43346292)
16. Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, DeLos Santos R, Federman S, Shinohara K, Carroll PR, Ha CM, Swanson MG. Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR Biomed. In press.
17. Costello LC, Akuffo V, Franklin RB. Testosterone stimulates net citrate production from aspartate by prostate epithelial cells. Horm Metab Res 1988;20:252-253. (Pubitemid 18129315)
18. Franklin RB, Lao LX, Costello LC. Evidence for two aspartate transport systems in prostate epithelial cells. Prostate 1990;16:137-145.
19. 31P-NMR studies of human colon cancer in-vitro and in-vivo. Surg Oncol 1993;2:7-18.
20. Wehrle JP, Ng CE, McGovern KA, Aiken NR, Shungu DC, Chance EM, Glickson JD. Metabolism of alternative substrates and the bioenergetic status of EMT6 tumor cell spheroids. NMR Biomed 2000;13:349-360.
21. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006;5:17.
22. Costello LC, Franklin RB. Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism: proceed with caution! Mol Cancer 2006;5:59.
23. Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005;5:143-153. (Pubitemid 40823303)
24. Costello LC, Guan Z, Kukoyi B, Feng P, Franklin RB. Terminal oxidation and the effects of zinc in prostate versus liver mitochondria. Mitochondrion 2004;4:331-338. (Pubitemid 40045659)
25. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006;59:10-16. (Pubitemid 43076233)
26. Singh KK, Desouki MM, Franklin RB, Costello LC. Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer 2006;5:14.
27. Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005;12:19-47.
28. Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation 2008;76:820-830.